Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide

Eric I. Zimmerman, Shuiying Hu, Justin L. Roberts, Alice A. Gibson, Shelley J. Orwick, Lie Li, Alex Sparreboom, and Sharyn D. Baker

Abstract

**Purpose:** Many tyrosine kinase inhibitors (TKI) undergo extensive hepatic metabolism, but mechanisms of their hepatocellular uptake remain poorly understood. We hypothesized that liver uptake of TKIs is mediated by the solute carriers OATP1B1 and OATP1B3.

**Experimental Design:** Transport of crizotinib, dasatinib, gefitinib, imatinib, nilotinib, pazopanib, sorafenib, sunitinib, vandetanib, and vemurafenib was studied in vitro using artificial membranes (PAMPA) and HEK293 cell lines stably transfected with OATP1B1, OATP1B3, or the ortholog mouse transporter, Oatp1b2. Pharmacokinetic studies were conducted with Oatp1b2-knockout mice and humanized OATP1B1- or OATP1B3-transgenic mice.

**Results:** All 10 TKIs were identified as substrates of OATP1B1, OATP1B3, or both. Transport of sorafenib was investigated further, as its diffusion was particularly low in the PAMPA assay (<4%) than other TKIs that were transported by both OATP1B1 and OATP1B3. Whereas Oatp1b2 deficiency in vivo had minimal influence on parent and active metabolite N-oxide drug exposure, plasma levels of the glucuronic acid metabolite of sorafenib (sorafenib-glucuronide) were increased more than 8-fold in Oatp1b2-knockout mice. This finding was unrelated to possible changes in intrinsic metabolic capacity for sorafenib-glucuronide formation in hepatic or intestinal microsomes *ex vivo*. Ensuing experiments revealed that sorafenib-glucuronide was itself a transported substrate of Oatp1b2 (17.5-fold vs. control), OATP1B1 (10.6-fold), and OATP1B3 (6.4-fold), and introduction of the human transporters in Oatp1b2-knockout mice provided partial restoration of function.

**Conclusions:** These findings signify a unique role for OATP1B1 and OATP1B3 in the elimination of sorafenib-glucuronide and suggest a role for these transporters in the *in vivo* handling of glucuronic acid conjugates of drugs. *Clin Cancer Res; 19(6); 1458–66. ©2013 AACR.*

Introduction

Over the last decade, human genome sequence data have suggested that many of the abnormalities associated with cancer are due to the abnormal function of protein kinases, and a major thrust of the current oncology drug discovery era has been to identify small-molecule tyrosine kinase inhibitors (TKI). To date, already 18 of such agents have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of a variety of diseases that were previously essentially resistant to standard chemotherapy. Nonetheless, the recent advances in cancer care have been relatively modest in a number of diseases, and many TKIs, like their cytotoxic counterparts, have rather limited efficacy combined with a significant degree of unexpected and unexplained toxicity (1).

Despite the revolutionary changes in the various stages of drug development used for TKIs (2), the standard strategy still in use for dose selection is to establish a therapeutic dose in phase II trials and subsequently, at best, modify it for individual differences in body surface area in children. However, there is already a wealth of experimental data indicating that both the efficacy and safety of TKIs might be optimized if dosing strategies would take into consideration the unique pharmacokinetic profiles of these agents (3, 4). Indeed, although TKIs offer possibly a number of important theoretical advantages over conventional cytotoxic agents, they are still afflicted by some of the same problems, including an extensive interindividual pharmacokinetic variability and the existence of a rather narrow therapeutic window (5).

It is likely that a critical determinant of pharmacokinetic variability observed with TKIs is associated with differential expression of drug-metabolizing enzymes and/or transporters at sites of absorption and elimination. Although the
Translational Relevance

The interindividual pharmacokinetic variability seen with most approved tyrosine kinase inhibitors (TKI) remains high, and this phenomenon may have important ramifications for the clinical activity and toxicity of these agents. We hypothesized that differential expression of polymorphic transporters involved in the hepatic elimination of TKIs plays a crucial role in explaining this pharmacologic variability. Here, we investigated the contribution of organic anion transporting polypeptides of the OATP1B family to the transport of 10 U.S. Food and Drug Administration–approved TKIs using an array of experimental model systems. Our results indicate the existence of at least 2 uptake transporters in the human liver (OATP1B1 and OATP1B3) with similar affinity for most of the tested TKIs that likely regulate the initial step in hepatic elimination. Deficiency of these transporters in vivo was associated with a particularly striking change in disposition phenotype for the glucuronic acid–conjugated metabolite of sorafenib. These findings signify a unique role for OATP1B-type transporters in the handling of drug glucuronides and have implications for the design of future clinical studies exploring the drug–drug interaction potential of TKIs, as well as for pharmacogenomic association analyses involving this class of agents.

Materials and Methods

Chemicals and cell lines

Crizotinib, nilotinib, sorafenib, and vemurafenib were obtained from Chemie Tek, dasatinib, pazopanib, and vandetanib from LC Laboratories and sunitinib and gefitinib from Toronto Research Chemicals. Imatinib was kindly provided by Novartis Pharmaceuticals. General tritium-labeled crizotinib, dasatinib, gefitinib, imatinib, nilotinib, pazopanib, sorafenib, vandetanib, and vemurafenib (specific activity, >1 Ci/mmol; radiochemical purity, >97.1%) were custom made by Moravek Biochemicals. [3H]Sunitinib (specific activity, 12.5 Ci/mmol; radiochemical purity, 99.0%) and [3H]estradiol-17β-glucuronide (specific activity, 50.1 Ci/mmol; radiochemical purity, 99.0%), a positive control substrate for OATP1B1 and OATP1B3 (12), were obtained from American Radiolabeled Chemicals. Dimethyl sulfoxide (DMSO; Sigma-Aldrich) was used as solvent for all TKIs.

The generation of stable, isogenic Flp-in T-Rex293 cells expressing OATP1B1^14a (wild-type), OATP1B1^C5 (C.521T>C; V174A); rs4149056), or OATP1B1^15 (N130D, V174A) has been described previously (13). Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM; Invitrogen) supplemented with 10% FBS, hygromycin B (25 μg/mL; Invitrogen), and blasticidin (37.5 μg/mL; Biovision). A secondary model of OATP1B1- or OATP1B3-expressing cells was created by transfecting HEK293 cells with the pIRE2-EGFP vector (BD Biosciences) containing SLCO1B1 cDNA, respectively, as described previously (14). Cells were maintained in DMEM supplemented with 10% FBS and G418 sulfate (1,000 μg/mL; A.G. Scientific). Similarly, HEK293 cells were transfected with the pDream.2/MCS vector (GenScript) containing SLCO1B1 cDNA, and a stable cell line was selected and maintained in DMEM supplemented with 10% FBS and G418 sulfate (500 μg/mL; A.G. Scientific). All cell lines were cultured and maintained at 37°C under 5% CO2.

In vitro transport in cellular models

Cells were seeded in 6-well plates in phenol red–free DMEM containing 10% FBS, hygromycin B (25 μg/mL), blasticidin (37.5 μg/mL), and doxycycline (1 μg/mL) and were incubated at 37°C for 24 hours. Cells were then washed with warm PBS and incubated with the TKI of interest in phenol-free DMEM (without FBS and supplements) at 37°C. In the initial TKI screen, a concentration of 0.1 μmol/L was used to evaluate OATP1B1-mediated transport under nonsaturating conditions. In select experiments for sorafenib, uptake experiments were carried out also at a concentration of 10 μmol/L, which is a concentration achievable in mice and humans receiving the drug orally. The experiment was terminated by placing cells on ice and washing twice with ice-cold PBS. Cells were collected and centrifuged at 1,050 rpm for 5 minutes at 4°C. The cell pellet was lysed in 1 N NaOH by vortex mixing, incubated at 4°C overnight, and then the solution was neutralized with 2 mol/L HCl. Total protein was measured using a Pierce BCA Protein Assay Kit (Thermo Scientific), and total protein
content was quantified using a Biotek µQuant microplate spectrophotometer. Intracellular drug concentrations were determined in the remaining cell lysate by liquid scintillation counting using an LS 6500 Multipurpose Scintillation Counter (Beckman). Intracellular concentrations of sorafenib-glucuronide were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS), as described previously (15), with modifications. Briefly, 100 µL of cell lysate was mixed with 100 µL MeOH in a 1.5-mL microcentrifuge tube. The tube was vortex-mixed for 45 seconds, followed by centrifugation at 13,000 rpm for 8 minutes at 4°C, and 1 µL supernatant was injected for analysis. Sorafenib-glucuronide stock solution (0.5 mg/mL in MeOH) was diluted with MeOH to prepare calibration standards at concentrations ranging from 1 to 2,000 ng/mL. Quality control (QC) samples were prepared independently at 3 different concentrations (low, medium, and high concentrations).

In vitro transport in a parallel artificial membrane permeability assay

Diffusion was assessed using Millipore 96-well multi-screen filter plates with polycrylonitrile membrane transporters and transport receiver plates (Millipore). The artificial membrane was prepared by adding 5 µL of 5% lecithin in dodecane (Avanti Polar Lipids Inc.) to the donor well. Then 150 µL of PBS solution containing the radiolabeled TKI of interest (1 µmol/L), [3H]midazolam (1 µmol/L), or [3H]methotrexate (500 µmol/L), each containing 5% DMSO, at pH 7.4 was added to the lipid-treated donor wells. The donor plate was placed onto the acceptor plate, and incubation was carried out over 16 hours as directed in the Millipore assay protocol at room temperature with the donor plate on the bottom. The donor plate was placed onto the acceptor plate, and incubation was carried out over 16 hours as directed in the Millipore assay protocol at room temperature with the donor plate on the bottom. After incubation, 75-µL samples from each donor well and 150-µL samples from each acceptor well were analyzed using liquid scintillation counting. The equilibrium transport of Brilliant Cresyl Blue and Lucifer Yellow was measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) as described previously (15), with modifications. Briefly, 10 µL of plasma was extracted with 60 µL MeOH to prepare calibration standards at concentrations ranging from 10 to 5,000 ng/mL. Plasma samples were centrifuged at 3,000 × g for 5 minutes, and plasma was separated and stored at −80°C until analysis. A separate group of mice was euthanized by CO2 asphyxiation, and livers were immediately collected and flash-frozen on dry ice. Liver specimens were stored at −80°C until further processing.

Pharmacokinetic studies

Female mice knockout for Oatp1a1 and Oatp1b1 transporters [Oatp1a1/−/− and Oatp1b1/−/−] were housed in a temperature-controlled environment with unrestricted access to drinking water. At select time points after sorafenib administration, blood samples (30 µL each) were taken from individual mice at 0.25, 0.5, and 1.5 hours from the submandibular vein using a lancet and at 3 and 4.5 hours from the retro-orbital venous plexus using a capillary. A final blood draw was obtained at 7.5 hours by a cardiac puncture using a syringe and needle. The total blood volume collected during the procedure from each mouse was 150 µL. All blood samples were centrifuged at 3,000 × g for 5 minutes, and plasma was separated and stored at −80°C until analysis. A separate group of mice was euthanized by CO2 asphyxiation, and livers were immediately collected and flash-frozen on dry ice. Liver specimens were stored at −80°C until further processing.

Statistical analysis

All data are presented as mean ± SE. Statistical analysis was conducted using GraphPad Prism 5.0 (GraphPad Software Inc.). All t tests were 2-tailed, and P < 0.05 was considered statistically significant.
Results

**In vitro transport of TKIs by OATP1B-type transporters**

We initially determined whether OATP1B1 can transport TKIs by measuring cellular uptake in HEK293 cells that overexpress OATP1B1. Estradiol-17β-D-glucuronide was used as a prototypical model substrate for OATP1B-mediated transport (12) and was evaluated in each experiment as a positive control (Supplementary Fig. S1). As shown in Fig. 1A, each TKI, with the exception of vandetanib and vemurafenib, had statistically significantly enhanced cellular uptake compared with that observed in vector control (VC) cells. Among the tested TKIs, the highest uptake by OATP1B1 was observed for sorafenib, about 1.5-fold greater than that observed in VC cells. This is in the same order of magnitude as the contribution of OATP1B1 to the uptake of the irinotecan metabolite, SN-38, using similar *in vitro* experiments (20).

Because the OATP1B3 isoform has 80% amino acid identity with OATP1B1 (12) and shares multiple overlapping substrates, including the anticancer agent docetaxel (14), we next measured TKI uptake using HEK293 cells that overexpress OATP1B3. These cells displayed uptake of a broad set of TKIs, similar to the OATP1B1-expressing cells, with the exception of sunitinib (Fig. 1A), which was not recognized as a transported substrate under the experimental conditions applied.

To assess the extent of TKI diffusion across cell membranes, a PAMPA assay was conducted under steady-state conditions. The lowest percentage transfer was observed for sorafenib (≈4%) and vemurafenib (≈1%), compared with 0.56% for methotrexate and about 50% for midazolam, agents representative of those known to diffuse poorly or diffuse freely across cell membranes, respectively (Supplementary Fig. S2). The low permeability observed for sorafenib and vemurafenib suggests that membrane transport of these agents is likely to be particularly dependent on solute carriers. Because of these TKIs, only sorafenib was a confirmed substrate for both OATP1B1 and OATP1B3, further studies focused specifically on sorafenib. More comprehensive profiling showed that transport of sorafenib

---

**Figure 1.** Transport of sorafenib by OATP1B transporters. A, [3H]-Labeled TKIs (0.1 μmol/L) were incubated with HEK293 cells expressing OATP1B1, OATP1B3, or VC for 30 minutes. Intracellular concentrations of drug were determined by liquid scintillation counting. Data represent the mean ± SE of 2 experiments with triplicate samples (n = 6). *, P < 0.05; **, P < 0.01; ***, P < 0.001. B and C, T-Rex293 cells expressing OATP1B1-1A or VC were incubated with 0.1 μmol/L for the indicated time (B) or the indicated concentration of [3H]sorafenib for 15 minutes (C). Data represent the mean sorafenib uptake (symbols) ± SE (error bars, shown when larger than symbol) of triplicate samples (n = 3). VC represents the cells transfected with an empty vector, representing background transport. The OATP1B1-VC data points, representing the specific contribution of OATP1B1 to the observed transport of sorafenib, were determined by averaging the triplicate values for each group, then subtracting the uptake values obtained in cells transfected with VC from the uptake values obtained in cells expressing OATP1B1.
(0.1 μmol/L) by OATP1B1 was time-dependent (Fig. 1B) as well as saturable (15-minute incubations; Fig. 1C), with a Michaelis–Menten constant ($K_m$) of 23.5 μmol/L and a maximum velocity ($V_{max}$) of 128 pmol/mg/min.

**Sorafenib pharmacokinetics in Oatp1b2-knockout mice**

To test whether sorafenib is transported by OATP1B-type carriers in vivo, we determined the pharmacokinetic profile of sorafenib in mice deficient in the ortholog transporter Oatp1b2 [Oatp1b2(−/−) mice]. Unexpectedly, minimal differences in peak plasma concentration and plasma area under the curve (AUC) for sorafenib, sorafenib N-oxide, and total active compounds (sorafenib + sorafenib N-oxide) were observed between Oatp1b2(−/−) and wild-type mice after a single oral sorafenib dose of 10 mg/kg (Fig. 2A; Table 1; Supplementary Fig. S3). Interestingly, a dramatic increase in the plasma levels of sorafenib-glucuronide was observed in the Oatp1b2(−/−) mice at each time point, resulting in a 5.5-fold increase in AUC compared with wild-type mice (Fig. 2B; Table 1). Furthermore, the metabolic ratio for sorafenib-glucuronide to sorafenib was substantially increased in the Oatp1b2(−/−) mice compared with wild-type mice (Table 1), whereas the metabolic ratio for sorafenib N-oxide was unchanged by Oatp1b2 deficiency (Supplementary Fig. S4). Importantly, the metabolic ratio of sorafenib-glucuronide in wild-type mice (0.17 ± 0.02) was within the same order of magnitude as that observed in humans (0.30 ± 0.19; ref. 15). As anticipated, the liver-to-plasma concentration ratio of sorafenib-glucuronide was substantially reduced in Oatp1b2(−/−) mice compared with wild-type mice (mean, 5.6-fold), but this was not observed for sorafenib or sorafenib N-oxide (Supplementary Fig. S5).

To test whether differences in sorafenib pharmacokinetics between wild-type mice and Oatp1b2(−/−) mice were due to alteration in sorafenib glucuronidation or oxidation, ex vivo assays were conducted using intestinal and liver microsomes. As shown in Fig. 3A, the rate of sorafenib glucuronidation in liver microsomes was not substantially different between mouse genotypes, and reaction velocity was negligible in intestinal microsomes. Although sorafenib N-oxide formation in liver microsomes was slightly increased in samples from Oatp1b2(−/−) mice (Supplementary Fig. S6), the reaction velocity for this metabolic pathway was insignificant in these mice and about 10-fold lower than that observed for sorafenib glucuronidation; intestinal sorafenib oxidation was undetectable (Supplementary Fig. S6). This suggests that the altered systemic levels of sorafenib-glucuronide in Oatp1b2(−/−) mice cannot be explained by an intrinsically altered ability to metabolize sorafenib.

Table 1. Sorafenib pharmacokinetic parameters in mice after a single oral administration of 10 mg/kg

<table>
<thead>
<tr>
<th>Strain</th>
<th>Genotype</th>
<th>C$_{max}$ μg/mL</th>
<th>AUC μg h/mL</th>
<th>S-glu:sorafenib</th>
<th>S-glu:sorafenib AUC ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>DBA</td>
<td>WT</td>
<td>6.70 ± 0.27</td>
<td>24.0 ± 2.20</td>
<td>1.10 ± 0.40</td>
<td>4.20 ± 1.00</td>
</tr>
<tr>
<td>DBA</td>
<td>Oatp1b2(−/−)</td>
<td>5.10 ± 0.50*</td>
<td>18.0 ± 2.00</td>
<td>6.00 ± 1.60*</td>
<td>23.0 ± 5.60*</td>
</tr>
<tr>
<td>FVB</td>
<td>WT</td>
<td>5.10 ± 0.75</td>
<td>23.0 ± 4.40</td>
<td>0.19 ± 0.12</td>
<td>0.83 ± 0.42</td>
</tr>
<tr>
<td>FVB</td>
<td>Oatp1a1b(−/−)</td>
<td>5.60 ± 0.53</td>
<td>18.0 ± 2.00</td>
<td>4.70 ± 0.63**</td>
<td>24.0 ± 2.30**</td>
</tr>
<tr>
<td>FVB</td>
<td>OATP1B1g9</td>
<td>5.60 ± 0.59</td>
<td>16.0 ± 1.40</td>
<td>3.30 ± 0.40**</td>
<td>14.0 ± 1.30**</td>
</tr>
<tr>
<td>FVB</td>
<td>OATP1B3g9</td>
<td>5.70 ± 0.32</td>
<td>19.0 ± 1.60</td>
<td>2.70 ± 0.12**</td>
<td>12.0 ± 1.40**</td>
</tr>
</tbody>
</table>

NOTE: Values are mean ± SEM. * P < 0.05; ** P < 0.001. Abbreviations: C$_{max}$ maximum plasma concentration; S-glu, sorafenib-glucuronide.
In vitro transport of sorafenib and sorafenib-glucuronide by OATP1B1 and OATP1B3 transplacental transporters

The mouse Oatp1b2 transporter shares 65% amino acid homology with the human OATP1B1 transporter (21) and has overlapping substrate specificity (22). To determine whether Oatp1b2 transports sorafenib, we measured sorafenib uptake in HEK293 cells transfected with Oatp1b2. In line with the in vitro data, sorafenib uptake was not increased compared with VC cells, whereas sorafenib uptake was facilitated by OATP1B1 and OATP1B3 under the same experimental conditions (Fig. 3B). In contrast, cells expressing Oatp1b2 had a 17.5-fold greater cellular uptake of sorafenib-glucuronide than VC cells (Fig. 3C). Similarly, sorafenib-glucuronide uptake was identified as a transported substrate for OATP1B1 and OATP1B3, with a 10.6- and 6.4-fold increase in cellular incorporation over VC cells, respectively (Fig. 3C).

Sorafenib and sorafenib-glucuronide uptake was also determined using cell lines expressing clinically relevant protein variants of OATP1B1 associated with single-nucleotide substitutions. Compared with the wild-type OATP1B1 (OATP1B1*1A), the cells transfected with reduced function variant haplotypes containing a c.521C substitution (OATP1B1*5 and OATP1B1*15) incorporated less sorafenib (Fig. 3D). Similar observations were made in these cells when testing the uptake of estradiol-17\beta-D-glucuronide (Supplementary Fig. S7).

Sorafenib pharmacokinetics in humanized OATP1B1*15 and OATP1B3*15 mice

Because sorafenib was not transported by Oatp1b2 in vitro, we next determined the pharmacokinetics of sorafenib in humanized transgenic mice with liver-specific expression of OATP1B1 (OATP1B1*15) or OATP1B3 (OATP1B3*15) on a strain deficient for all Oatp1a and Oatp1b transporters [Oatp1a/b(−/−) mice]. Despite the ability of OATP1B1 and OATP1B3 to transport sorafenib in vitro, sorafenib maximum plasma concentration and AUC were not significantly different between OATP1B1*15 or OATP1B3*15 mice and Oatp1a/b(−/−) mice, as well as between wild-type and Oatp1a/b(−/−) mice (Fig. 4A; Table 1). Similar to the observed pharmacokinetic parameters in Oatp1b2(−/−) mice, Oatp1a/b(−/−) mice displayed a 28.9-fold increase in the AUC of sorafenib-glucuronide compared with the corresponding wild-type (Fig. 4A and B; Table 1). Notably, the introduction of OATP1B1 or OATP1B3 into livers of Oatp1a/b(−/−) mice was associated with a sorafenib-glucuronide AUC that was 16.9- and 14.5-fold higher, respectively, compared with wild-type mice (Fig. 4B; Table 1), thereby providing partial restoration of function. Evaluation of sorafenib metabolism ex vivo in liver and intestinal microsomes from wild-type and Oatp1b2(−/−) mice showed no differences between mouse genotypes (Supplementary Fig. S8). Interestingly, the sorafenib-glucuronide to sorafenib AUC ratio was about 4.5-fold higher.
in DBA wild-type mice than in FVB wild-type mice (Table 1). This finding is consistent with the notion that the sorafenib-glucuronide formation rate was faster in liver microsomes from DBA wild-type mice (Fig. 3A) compared with the FVB strain (Supplementary Fig. S8A). It is possible, however, that additional mechanisms, beyond the scope of this investigation, may have contributed to these phenotypic differences, including mouse strain–dependent differences in the expression of sorafenib transporters in the liver.

Discussion

In this study, we show that several TKIs, including sorafenib, are substrates for the human OATP1B1 and OATP1B3 transporters. Using an HEK293 cell model over-expressing the OATP1B-type proteins, we determined that sorafenib is incorporated into cells in both a time- and a concentration-dependent manner. These data, however, are in contrast to our previous study to identify sorafenib carriers using a *Xenopus laevis* oocyte model transfected with OATP1B1 cRNA (23). This discrepancy suggests that cell context may affect OATP-mediated transport of xenobiotics, and similar cell context–dependent observations have been made with the OATP1B1 substrate docetaxel (14). Furthermore, using the T-Rex293 cell model, sorafenib transport was decreased in cells expressing naturally occurring OATP1B variants (OATP1B1’5 and OATP1B1’15) exhibiting reduced function.

Our *in vivo* studies using the Oatp1b2(−/−) mouse model showed minimal differences in the pharmacokinetic profile of sorafenib compared with wild-type mice. We previously showed by microarray analysis that Oatp1b2 deficiency in mice is not associated with any pronounced compensatory alterations in metabolic enzyme or transporter expression in the liver (24). Moreover, there were no changes in the functional expression of the key cytochrome P450 enzymes associated with sorafenib metabolism, including Cyp3a isoforms, in these transporter knockout mice (24). Furthermore, our *in vivo* data were supported by a lack of sorafenib transport in HEK293 cells transfected with the Oatp1b2 transporter. It should be pointed out that one possible limitation of the Oatp1b2(−/−) mouse model is the fact that, unlike in humans, mouse hepatocytes express multiple members of Oatp1a, a related subfamily of transporters that can potentially provide compensatory restoration of function when Oatp1b2 is lost (25). However, in our current study, we found no substantial differences in sorafenib pharmacokinetic parameters when comparing results in Oatp1b2(−/−) mice with those in sex- and age-matched Oatp1a/b(−/−) mice, which are additionally deficient in all members of the Oatp1a subfamily. This finding eliminates the possibility that the lack of a change in sorafenib plasma levels in Oatp1b2(−/−) mice, compared with wild-type animals, was due to compensatory alteration by Oatp1a transporters.

Although the rodent and human OATP1B-type transporters share a high degree of sequence homology, similarity in basolateral membrane localization, and have largely overlapping substrate specificity (26), our current *in vitro* data suggest that sorafenib is a substrate for both the human OATP1B1 and OATP1B3 transporters but not for mouse Oatp1b2. Such demonstration of inherent interspecies differences in the affinity for OATP1B-type transporters is not unprecedented, as prior findings showed that the OATP1B3 substrate digoxin is not transported by the rodent Oatp1b2 ortholog (27). Considering the relatively low intrinsic permeability of sorafenib observed here in a PAMPA assay and its apparent lack of interaction with the mouse Oatp1a or Oatp1b transporters, additional uptake transporters likely exist that contribute to the hepatic uptake of sorafenib in mice. The low permeability observed for sorafenib also supports the existence of uptake transporters with a role in the drug’s intestinal absorption after oral administration and such transport component may have additional contribution to the overall pharmacokinetic variability.

In contrast to sorafenib, the systemic exposure to sorafenib-glucuronide was dramatically increased in Oatp1b2(−/−) mice compared with their wild-type counterparts. No apparent differences in the *in vivo* sorafenib-glucuronide formation rate were observed between Oatp1b2(−/−) and wild-type mice, suggesting that the observed kinetic differences were due to aberrant transport. Moreover, compared with the corresponding wild-type mice, an increase in the plasma concentrations of sorafenib-glucuronide was also observed in Oatp1a/b(−/−) mice. A similar phenomenon has recently been reported to occur for conjugated bilirubin (18), whereby Oatp1a/b deficiency leads to excessive build-up of bilirubin-glucuronide in the systemic circulation, which can ultimately result in jaundice. Indeed, a
substantial fraction of bilirubin that is being conjugated in hepatocytes can be secreted back into the circulation (by ABCG2) and be subsequently taken up again in downstream hepatocytes by OATP1B-type transporters. This unusual mechanism, dubbed “hepatocyte hopping” (25), facilitates efficient detoxification by circumventing saturation of alternate detoxification pathways, including terminal excretion of phase II–conjugated metabolites into the bile. It is likely that the same hepatocyte-hopping principle shown for bilirubin-glucuronide applies also to sorafenib-glucuronide. Among the class of TKIs, this pharmacokinetic process may be particularly important for sorafenib as it is one of only few currently FDA-approved TKIs for which glucuronidation contributes substantially to drug elimination in addition to CYP3A4-mediated biotransformation (15).

The potential clinical ramification of the hepatocyte-hopping phenomenon of sorafenib-glucuronide requires additional investigation. For example, sorafenib undergoes enterohepatic recirculation (28) following bacterial β-glucuronidase–mediated deconjugation of sorafenib-glucuronide within the intestinal lumen (29), and interference of this deconjugation by neomycin treatment decreases the systemic exposure to sorafenib by more than 50% (Nexavar package insert: see: berlex.bayerhealthcare.com). It can be envisaged that interference of the biliary excretion of sorafenib-glucuronide by inhibition of OATP1B-mediated uptake into hepatocytes could potentially lead to diminished enterohepatic recycling of sorafenib and reduced sorafenib systemic exposure. In this context, it is noteworthy that there was a trend for a lower sorafenib AUC by 25% in the Oatp1b2(−/−) mice and by 22% in the Oatp1a/b(−/−) mice compared with their respective wild-type controls. A similar phenomenon has been recently reported for mycophenolate mofetil, an immunosuppressive drug that undergoes extensive glucuronidation. In this case, a cohort of renal transplant patients with a genotype associated with decreased OATP1B1 function had reduced circulating levels of the active moiety, mycophenolic acid, and a concomitant increase in the levels of its glucuronide metabolite, presumably due to a disturbance in enterohepatic cycling (30).

On the basis of in vitro uptake studies, multiple functionally different haplotypes, including OATP1B1*5 and OATP1B1*15, were found to have a detrimental impact on sorafenib transport. This finding is consistent with previous studies showing substantially diminished transport activity of several OATP1B1 substrates by these particular variants when transfected into mammalian cells (31). Moreover, in humans, these variants have been associated with altered systemic exposure and toxicity in response to multiple substrates (32). In our current study, introduction of OATP1B1 or OATP1B3 into the liver of Oatp1a/b(−/−) mice resulted only in partially restored function to elimi-nate sorafenib-glucuronide. It is possible that this partial restoration is due to differences in affinity of sorafenib-glucuronide for Oatp1b2 relative to OATP1B1 and OATP1B3 and/or that the hepatic expression of OATP1B1 or OATP1B3 in the transgenic mice is lower than that of Oatp1b2 in the parental strain. Regardless, these data suggest the possibility that even partial deficiency of either OATP1B1 or OATP1B3 function, for example, as a result of an inherited genetic defect, can lead to a buildup of sorafenib-glucuronide in the circulation that leads to altered recycling of sorafenib.

Overall, our findings signify an unusual role for OATP1B1 and OATP1B3 in the elimination of sorafenib, whereby sorafenib-glucuronide can enter a sinusoidal liver–blood shuttling loop that becomes defective when OATP1B function is compromised, leading to excessive systemic accumulation. Future study of the association between sorafenib-glucuronide levels and sorafenib-associated toxicity and efficacy, and the connection with polymorphic OATP1B-type transport, is warranted.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Disclaimer
The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Authors’ Contributions
Conception and design: E.I. Zimmerman, A. Sparreboom, S.D. Baker
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E.I. Zimmerman, S. Hu, J.L. Roberts, A.A. Gibson, S.J. Orwick, A. Sparreboom
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E.I. Zimmerman, S. Hu, J.L. Roberts, A.A. Gibson, A. Sparreboom, S.D. Baker
Writing, review, and/or revision of the manuscript: E.I. Zimmerman, S. Hu, J.L. Roberts, A.A. Gibson
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): J.L. Roberts, A.A. Gibson
Study supervision: S.D. Baker

Acknowledgments
The authors thank Richard Kim and Jeffrey Stock for providing the Oatp1b2(−/−) mice.

Grant Support
This study was supported in part by the American Lebanese Syrian Associated Charities (ALSAC), USPHS Cancer Center Support Grant 3P30CA021765 (to S.D. Baker), and NCI Grants SRO1CA138744 (to S.D. Baker), SRO1CA151633 (to A. Sparreboom), and SRO1CA239344.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received October 22, 2012; revised January 10, 2013; accepted January 11, 2013; published OnlineFirst January 22, 2013.

References


Clinical Cancer Research

Contribution of OATP1B1 and OATP1B3 to the Disposition of Sorafenib and Sorafenib-Glucuronide


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-12-3306

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2013/01/22/1078-0432.CCR-12-3306.DC1

Cited articles
This article cites 32 articles, 14 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/19/6/1458.full#ref-list-1

Citing articles
This article has been cited by 14 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/19/6/1458.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.